Telehealth provider Hims & Hers began offering a compounded oral version of Novo Nordisk’s Wegovy, prompting Novo to threaten legal action and the FDA to signal enforcement against unapproved copycat products. Hims’ move targets demand for oral GLP‑1 alternatives and follows the rapid market expansion of injectable GLP‑1 medicines; Novo framed the offering as an unlawful, inauthentic product and warned of litigation. The clash amplifies regulatory scrutiny around compounded versions of novel obesity drugs and could accelerate agency guidance or interventions. For biopharma and telehealth players, the episode illustrates how high‑value launches can spur rapid off‑label or compounded responses that raise safety, IP, and regulatory concerns.